Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to -$853000.0.

  • Ani Pharmaceuticals' Other Non Operating Income rose 8857.79% to -$853000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 11422.39%. This contributed to the annual value of -$7.5 million for FY2024, which is 459685.53% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Other Non Operating Income stood at -$853000.0, which was up 8857.79% from $1.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Other Non Operating Income high stood at $1.7 million for Q2 2025, and its period low was -$7.5 million during Q3 2024.
  • Over the past 5 years, Ani Pharmaceuticals' median Other Non Operating Income value was -$47500.0 (recorded in 2022), while the average stood at -$574222.2.
  • In the last 5 years, Ani Pharmaceuticals' Other Non Operating Income plummeted by 1904871.79% in 2024 and then soared by 207613.64% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Other Non Operating Income stood at -$2.7 million in 2021, then surged by 98.44% to -$42000.0 in 2022, then grew by 21.43% to -$33000.0 in 2023, then crashed by 22530.3% to -$7.5 million in 2024, then skyrocketed by 88.58% to -$853000.0 in 2025.
  • Its Other Non Operating Income stands at -$853000.0 for Q3 2025, versus $1.7 million for Q2 2025 and $198000.0 for Q1 2025.